EMD Stock Overview
Emyria Limited, a clinical-stage biotech company, engages in the development of treatments for unmet medical needs.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Emyria Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$0.056 |
| 52 Week High | AU$0.18 |
| 52 Week Low | AU$0.041 |
| Beta | 0.76 |
| 1 Month Change | -6.67% |
| 3 Month Change | 1.82% |
| 1 Year Change | -67.06% |
| 3 Year Change | -72.00% |
| 5 Year Change | n/a |
| Change since IPO | -61.38% |
Recent News & Updates
Recent updates
Will Emyria (ASX:EMD) Spend Its Cash Wisely?
Feb 02
We're Hopeful That Emyria (ASX:EMD) Will Use Its Cash Wisely
May 20Here's Why We're Not Too Worried About Emyria's (ASX:EMD) Cash Burn Situation
Oct 20We Think Emyria (ASX:EMD) Needs To Drive Business Growth Carefully
Jun 11Will Emyria (ASX:EMD) Spend Its Cash Wisely?
Feb 25Need To Know: Emyria Limited (ASX:EMD) Insiders Have Been Buying Shares
Nov 17Shareholder Returns
| EMD | AU Pharmaceuticals | AU Market | |
|---|---|---|---|
| 7D | -5.1% | -5.0% | -3.1% |
| 1Y | -67.1% | 32.4% | 4.0% |
Return vs Industry: EMD underperformed the Australian Pharmaceuticals industry which returned 32.4% over the past year.
Return vs Market: EMD underperformed the Australian Market which returned 4% over the past year.
Price Volatility
| EMD volatility | |
|---|---|
| EMD Average Weekly Movement | 14.7% |
| Pharmaceuticals Industry Average Movement | 10.9% |
| Market Average Movement | 8.9% |
| 10% most volatile stocks in AU Market | 17.4% |
| 10% least volatile stocks in AU Market | 3.5% |
Stable Share Price: EMD's share price has been volatile over the past 3 months.
Volatility Over Time: EMD's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of Australian stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2018 | n/a | Michael Winlo | emyria.com |
Emyria Limited, a clinical-stage biotech company, engages in the development of treatments for unmet medical needs. The company develops psychedelic-assisted therapy, as well as MDMA drug discovery program. Its drug development program includes EMD-RX5 for treatment of psychological distress and mild stress and anxiety.
Emyria Limited Fundamentals Summary
| EMD fundamental statistics | |
|---|---|
| Market cap | AU$21.63m |
| Earnings (TTM) | -AU$11.95m |
| Revenue (TTM) | AU$1.95m |
10.5x
P/S Ratio-1.7x
P/E RatioIs EMD overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| EMD income statement (TTM) | |
|---|---|
| Revenue | AU$1.95m |
| Cost of Revenue | AU$2.19m |
| Gross Profit | -AU$242.81k |
| Other Expenses | AU$11.71m |
| Earnings | -AU$11.95m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.033 |
| Gross Margin | -12.45% |
| Net Profit Margin | -612.98% |
| Debt/Equity Ratio | 204.4% |
How did EMD perform over the long term?
See historical performance and comparison